OBJECTIVE: COVID-19 toes represent the main dermatological COVID-19 cutaneous manifestation in pediatric patients. Its diagnosis exposes the whole family to social stigma and this aspect was not previously evaluated.PATIENTS AND METHODS: This was a multicenter, case-control, observational study that compared the family impact of COVID-19 toes vs. psoriasis (PsO). We enrolled 46 pediatric patients (23 with psoriasis and 23 with COVID-19 toes, age and gender matched) and their parents/caregivers that had to fill the Dermatitis Family Impact (DFI) questionnaire.RESULTS: DFI index did not differ significantly between both subgroups (p= 0.48), and in psoriatic patients did not correlate with both Psoriasis Area Severity Index (PASI) (p= 0.59) and itchVAS (p= 0.16).CONCLUSIONS: COVID-19 toes, a transitory dermatosis, exerted a similar impact/ perturbation on family dynamics than PsO, a well-known stigmatizing, chronic inflammatory dermatosis.
Chilblain-like lesions (COVID-19 toes) have the same impact on family members than psoriasis systemically treated: insights from a case-control study targeting the pediatric population
Savoia, P;
2022-01-01
Abstract
OBJECTIVE: COVID-19 toes represent the main dermatological COVID-19 cutaneous manifestation in pediatric patients. Its diagnosis exposes the whole family to social stigma and this aspect was not previously evaluated.PATIENTS AND METHODS: This was a multicenter, case-control, observational study that compared the family impact of COVID-19 toes vs. psoriasis (PsO). We enrolled 46 pediatric patients (23 with psoriasis and 23 with COVID-19 toes, age and gender matched) and their parents/caregivers that had to fill the Dermatitis Family Impact (DFI) questionnaire.RESULTS: DFI index did not differ significantly between both subgroups (p= 0.48), and in psoriatic patients did not correlate with both Psoriasis Area Severity Index (PASI) (p= 0.59) and itchVAS (p= 0.16).CONCLUSIONS: COVID-19 toes, a transitory dermatosis, exerted a similar impact/ perturbation on family dynamics than PsO, a well-known stigmatizing, chronic inflammatory dermatosis.File | Dimensione | Formato | |
---|---|---|---|
Eur Rev Med Pharmacol Sci 2022.pdf
file ad accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Dominio pubblico
Dimensione
611.7 kB
Formato
Adobe PDF
|
611.7 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.